| Original language | English |
|---|---|
| Pages (from-to) | 987-988 |
| Number of pages | 2 |
| Journal | Alimentary Pharmacology & Therapeutics |
| Volume | 51 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 27 Apr 2020 |
Bibliographical note
Funding Information:This paper presents independent research funded (or supported) by the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham (Grant Reference Number BRC-1215-20009). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. Declaration of personal interests: Dr Newsome reports consultancy or speaker fees on behalf of the University of Birmingham from Boehringer Ingelheim, Gilead, Pfizer, Affimmune, Intercept, Johnson & Johnson, Novo Nordisk, Shire and Poxel Pharmaceuticals. His institution receives grant funding from Pharmaxis, Boehringer Ingelheim and Novo Nordisk. Dr Horn reports scientific collaboration with Novo Nordisk, Geratherm respiratory GmbH and UST Umweltsensortechnik and funding from Novo Nordisk.
ASJC Scopus subject areas
- Hepatology
- Gastroenterology
- Pharmacology (medical)